Prostate cancer is often a slow growing disease. Screening with PSA (prostate-specific antigen) testing results in diagnosis at an earlier stage. There has been much controversy over testing and whether screening is beneficial or harmful. In combination with a DRE (digital rectal exam), these early detection methods are effective at identifying patients who are at increased risk of having prostate cancer, in whom further testing is needed.
Advocacy groups and cancer organizations have differing opinions on PSA testing. Dr. Laurence Klotz, Chief of Urology, Sunnybrook Health Sciences Center, Professor of Surgery, University of Toronto recommends that: